Site-specific PEGylation for high-yield preparation of Lys 21-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr1 and Lys12

Bioconjugate Chemistry

Volumn 18, Issue 2, 2007, Pages 500-506

  Youn, Yu Seok ^a   Lee, Kang Choon ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RATS;

CONDITION; GLOMERULAR FILTRATION; GROWTH HORMONE RELEASING FACTORS; HIGHER YIELD; PEGYLATED; PEGYLATION; RAT LIVERS; REACTION TEMPERATURE; SITE-SPECIFIC; TRIETHYLAMINES;

ISOMERS;

CARBONYL DERIVATIVE; FLUORENYLMETHOXYCARBONYL DERIVATIVE; GROWTH HORMONE RELEASING FACTOR[1-29]; LYSINAMIDE PEGYLATED GROWTH HORMONE RELEASING FACTOR[1-29]; LYSINE; MACROGOL; TRIETHYLAMINE; TYROSINE; UNCLASSIFIED DRUG;

ALKALINITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CHEMICAL REACTION; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; HYPOPHYSIS CELL; KIDNEY HOMOGENATE; LIVER HOMOGENATE; MALE; MONOLAYER CULTURE; NONHUMAN; PEGYLATION; PLASMA; PROCESS OPTIMIZATION; RAT; REACTION ANALYSIS; REACTION TIME; SPRAGUE DAWLEY RAT; STRUCTURE ANALYSIS; WISTAR RAT;

RATTUS;

EID: 33947686654     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc060173z     Document Type: Article

References (31)

1. Ankersen, M., Hansen, T. K., Ahnfelt-Ronne, I., and Kappelgaard, A. M. (1999) Growth hormone secretagogues: recent advances and applications. Drug Discovery Today 4 (11), 497-506.
2. Jansen, M., Darby, I., Abribat, T., Dubreuil, P., Ferdinandi, E. S., and Hardy, J. G. (2004) Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int. J. Pharm. 276 (1-2), 75-81.
3. 2 and an agmatine29 GH-RH analog, after intravenous, subcutaneous, and intranasal administration and after pulmonary inhalation in rats. Int. J. Pept. Protein Res. 41 (3), 246-249.
4. Bongers, J., Lambros, T., Ahmad, M., and Heimer, E. P. (1992) Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim. Biophys. Acta 1122 (2), 147-153.
5. 2 terminus, J. Clin. Invest. 78 (4), 906-913.
6. Esposito, P., Barbero, L., Caccia, P., Caliceti, P., D'Antonio, M., Piguet, G., and Veronese, F. M. (2003) PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv. Drug Delivery Rev. 55 (10), 1279-1291.
7. D'Antonio, M., Louveau, I., Esposito, P., Bertolino, M., and Canali, S. (2004) Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigs. Growth Harm. IGF Res. 14 (3), 226-234.
8. Harris, J. M., and Chess, R. B. (2003) Effect of PEGylation on pharmaceuticals. Nat. Rev. Drug Discovery 2 (3), 214-221.
9. Veronese, F. M., and Pasut, G. (2005) PEGylation, successful approach to drug delivery. Drug Discovery Today 10 (21), 1451-1458.
10. Greenwald, R. B., Choe, Y. H., Mcguire, J., and Conover, C. D. (2003) Effective drug delivery by PEGylated drug conjugates. Adv. Drug Delivery Rev. 55 (2), 217-250.
11. Roberts, M. J., Bentley, M. D., and Harris, J. M. (2002) Chemistry for peptide and protein PEGylation. Adv. Drug Delivery Rev. 54 (4), 459-476.
12. Lee, K. C., Moon, S. C., Park, M. O., Lee, J. T., Na, D. H., Yoo, S. D., Lee, H. S., and DeLuca, P. P. (1999) Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharm. Res. 16 (6), 813-818.
13. Caliceti, P., Salmaso, S., Walker, G., and Bernkop-Schnurch, A. (2004) Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur. J. Pharm. Sci. 22 (4), 315-323.
14. Lee, H., Jang, I. H., Ryu, S. H., and Park, T. G. (2003) N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm. Res. 20 (5), 818-825.
15. Lee, S. H., Lee, S., Youn, Y. S., Na, D. H., Chae, S. Y., Byun, Y., and Lee, K. C. (2005) Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjugate Chem. 16 (2), 377-382.
16. Lee, S., Youn, Y. S., Lee, S.-H., Byun, Y., and Lee, K. C. (2006) PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia 49 (7), 1608-1611.
17. Felix, A. M., Lu, Y., and Campbell, R. M. (1995) Pegylated peptides IV. Enhanced biological activity of site-directed pegylated GRF analogs. Int. J. Pept. Protein Res. 46 (3-4), 253-264.
18. Campbell, R. M., Heimer, E. P., Ahmad, M., Eisenbeis, H. G., Lambros, T. J., Lee, Y., Miller, R. W., Stricker, P. R., and Felix, A. M. (1997) Pegylated peptides V. Carboxy-terminal PEGylated analogs of growth hormone-releasing factor (GRF) display enhanced duration of biological activity in vivo. J. Pept. Res. 49 (6), 527-537.
19. Lu, Y.-A., and Felix, A. M. (1994) Pegylated peptides II: Solid-phase synthesis of amino-, carboxy-, and side-chain pegylated peptides. Int. J. Pept. Protein Res. 43 (2), 127-138.
20. Lu, Y.-A., and Felix, A. M. (1994) Pegylated peptides III: Solid-phase synthesis with pegylating reagents of varying molecular weight: synthesis of multiply pegylated peptides. React. Polym. 22, 221-229.
21. Piguet, G., Gatti, M., Barbero, L., Traversa, S., Caccia, P., and Esposito, P. (2002) Set-up of large laboratory-scale chromatographic separations of poly(ethylene glycol) derivatives of the growth hormone-releasing factor 1-29 analogue. J. Chromatogr., A 944 (1-2), 141-148.
22. Youn, Y. S., Na, D. H., Yoo, S. D., Song, S.-C., and Lee, K. C. (2004) Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29). J. Chromatogr., A 1061 (1), 45-49.
23. Na, D. H., Youn, Y. S., Park, E. J., Lee, J. M., Cho., O. R., Lee, K. R., Lee, S. D., Yoo, S. D., DeLuca, P. P., and Lee, K. C. (2004) Stability of PEGylated salmon calcitonin in nasal mucosa. J. Pharm. Sci. 93 (2), 256-261.
24. 18-amine specific PEGylation: Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J. Controlled Release 114 (3), 334-342.
25. 125I-GST-TatdMt possessing potent anti-obesity activity. Regul. Pept. 129 (1-3), 25-30.
26. Youn, Y. S., Na, D. H., Yoo, S. D., Song, S.-C., and Lee, K. C. (2005) Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential. Int. J. Biochem. Cell Biol. 37 (7), 1525-1533.
27. Cheng, J., Wu, T.-J., Butler, B., and Cheng, K. (1997) Growth hormone releasing peptide: A comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells. Life Sci. 60 (16), 1385-1392.
28. 1) insensitive to GH-releasing hormone. Regul. Pept. 70 (1), 49-54.
29. Yamamoto, Y., Tsutsumi, Y., Yoshioka, Y., Nishibata, T., Kobahashi, K., Okamoto, T., Mukai, Y., Shimizu, T., Nakagawa, S., Nagata, S., and Mayumi, T. (2003) Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity. Nat. Biotechnol. 21 (5), 546-552.
30. Moreadith, R. W., and Collen, D. (2003) Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction. Adv. Drug Delivery Rev. 55 (10), 1337-1345.
31. Rosendahl, M. S., Doherty, D. H., Smith, D. J., Carlson, S. J., Chlipala, E. A., and Cox, G. N. (2005) A long-acting, highly potent interferon α-2 conjugate created using site-specific PEGylation. Bioconjugate Chem. 16 (1), 200-207.